{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:57:58Z","timestamp":1791644278714,"version":"4.3.4"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100031934","name":"First Affiliated Hospital of Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["2024-QN-39"],"award-info":[{"award-number":["2024-QN-39"]}],"id":[{"id":"10.13039\/100031934","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.micpath.2026.108318","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:23:26Z","timestamp":1769127806000},"page":"108318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Current and emerging pharmacological treatments for visceral leishmaniasis"],"prefix":"10.1016","volume":"212","author":[{"given":"Sijia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-9043","authenticated-orcid":false,"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib1","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/S1473-3099(23)00353-5","article-title":"The status of combination therapy for visceral leishmaniasis: an updated review","volume":"24","author":"van Griensven","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108318_bib2","first-page":"1","article-title":"Could combination chemotherapy be more effective than monotherapy in the treatment of visceral leishmaniasis? A systematic review of preclinical evidence","author":"Bastos","year":"2022","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2026.108318_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1016925","article-title":"Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis-An updated review","volume":"10","author":"Kumar","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12939-025-02691-0","article-title":"Global burden of leishmaniasis, 1990-2021: systematic analysis of the global burden of disease study","volume":"24","author":"Li","year":"2025","journal-title":"Int. J. Equity Health"},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ddr.21907","article-title":"Road-map of pre-clinical treatment for Visceral Leishmaniasis","volume":"83","author":"Mazire","year":"2022","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.micpath.2026.108318_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.690432","article-title":"The potential of traditional knowledge to develop effective medicines for the treatment of leishmaniasis","volume":"12","author":"Passero","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2022.102739","article-title":"Protease inhibitors as a potential agent against visceral Leishmaniasis: a review to inspire future study","volume":"27","author":"Sreedharan","year":"2023","journal-title":"Braz. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.14919","article-title":"Treatment options for leishmaniasis","volume":"47","author":"Pradhan","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"issue":"949","key":"10.1016\/j.micpath.2026.108318_bib9","first-page":"1","article-title":"Control of the leishmaniases","author":"World Health","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1590\/0074-02760170289","article-title":"Increased thiol levels in antimony-resistant Leishmania infantum isolated from treatment-refractory visceral leishmaniasis in Brazil","volume":"113","author":"Magalhaes","year":"2018","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.micinf.2007.01.009","article-title":"Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?","volume":"9","author":"Rijal","year":"2007","journal-title":"Microb. Infect."},{"issue":"13\u201314","key":"10.1016\/j.micpath.2026.108318_bib12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ijpara.2011.07.013","article-title":"Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells","volume":"41","author":"Mukhopadhyay","year":"2011","journal-title":"Int. J. Parasitol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1128\/AAC.01196-07","article-title":"Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection","volume":"52","author":"Mookerjee Basu","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2026.108318_bib14","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol Biol Int"},{"issue":"8","key":"10.1016\/j.micpath.2026.108318_bib15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1515\/pac-2018-1102","article-title":"Current and promising novel drug candidates against visceral leishmaniasis","volume":"91","author":"Reguera","year":"2019","journal-title":"Pure Appl. Chem."},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181e9441b","article-title":"Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis","volume":"89","author":"Safdar","year":"2010","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.micpath.2026.108318_bib17","first-page":"11","article-title":"Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis","volume":"10","author":"Shirzadi","year":"2019","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.micpath.2026.108318_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect. Dis. Poverty"},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1128\/AAC.01123-06","article-title":"Miltefosine affects lipid metabolism in Leishmania donovani promastigotes","volume":"51","author":"Rakotomanga","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.micpath.2026.108318_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02507-18","article-title":"Systematic review of host-mediated activity of miltefosine in leishmaniasis through immunomodulation","volume":"63","author":"Palic","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9143","key":"10.1016\/j.micpath.2026.108318_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.micpath.2026.108318_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315710","article-title":"Safety profile of miltefosine in the treatment of cutaneous leishmaniasis","volume":"19","author":"Ribeiro","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.micpath.2026.108318_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026660","article-title":"Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani","volume":"6","author":"Chawla","year":"2011","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.micpath.2026.108318_bib25","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2026.108318_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8629039","article-title":"Efficacy and safety of paromomycin for visceral leishmaniasis: a systematic review","author":"Pokharel","year":"2021","journal-title":"J. Trop. Med."},{"issue":"17","key":"10.1016\/j.micpath.2026.108318_bib27","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s40265-013-0133-0","article-title":"Therapeutic options for visceral leishmaniasis","volume":"73","author":"Monge-Maillo","year":"2013","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.micpath.2026.108318_bib28","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/tmi.12603","article-title":"Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan","volume":"20","author":"Atia","year":"2015","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.micpath.2026.108318_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/645203","article-title":"Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India","volume":"2011","author":"Sinha","year":"2011","journal-title":"J. Trop. Med."},{"key":"10.1016\/j.micpath.2026.108318_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2019.107768","article-title":"Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: a randomized, blinded, controlled study","volume":"206","author":"Kasabalis","year":"2019","journal-title":"Exp. Parasitol."},{"issue":"10","key":"10.1016\/j.micpath.2026.108318_bib31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/cbdv.200590111","article-title":"Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin","volume":"2","author":"Nguewa","year":"2005","journal-title":"Chem. Biodivers."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molbiopara.2005.08.016","article-title":"Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani","volume":"145","author":"Mukherjee","year":"2006","journal-title":"Mol. Biochem. Parasitol."},{"issue":"6","key":"10.1016\/j.micpath.2026.108318_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab065","article-title":"Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review","volume":"28","author":"Piccica","year":"2021","journal-title":"J. Trav. Med."},{"issue":"5","key":"10.1016\/j.micpath.2026.108318_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/clinids\/7.5.625","article-title":"Pentamidine: a review","volume":"7","author":"Sands","year":"1985","journal-title":"Rev. Infect. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2026.108318_bib35","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1128\/AAC.47.5.1529-1535.2003","article-title":"The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis","volume":"47","author":"Carter","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.exppara.2009.02.001","volume":"122","author":"Haldar","year":"2009","journal-title":"Exp. Parasitol."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1590\/S0036-46652011000300003","article-title":"In vitro and in vivo antileishmanial efficacy of a combination therapy of diminazene and artesunate against Leishmania donovani in BALB\/c mice","volume":"53","author":"Mutiso","year":"2011","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.exppara.2012.05.007","article-title":"Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis","volume":"131","author":"Shakya","year":"2012","journal-title":"Exp. Parasitol."},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00436-012-2868-z","article-title":"Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis","volume":"111","author":"Shakya","year":"2012","journal-title":"Parasitol. Res."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijantimicag.2014.10.023","article-title":"Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis","volume":"45","author":"Bhattacharjee","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.7555\/JBR.29.20140072","article-title":"In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis","volume":"29","author":"Mwololo","year":"2015","journal-title":"J Biomed Res"},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jac\/dkw448","article-title":"Pharmacological inhibition of p110delta subunit of PI3K confers protection against experimental leishmaniasis","volume":"72","author":"Khadem","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01129-17","article-title":"Antileishmanial efficacy and pharmacokinetics of DB766-Azole combinations","volume":"62","author":"Joice","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2026.108318_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fcimb.2019.00229","article-title":"Miltefosine-Lopinavir Combination Therapy against Leishmania infantum Infection: in vitro and in vivo Approaches","volume":"9","author":"Rebello","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/00034983.1998.11813276","article-title":"Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis","volume":"92","author":"Oliva","year":"1998","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"11","key":"10.1016\/j.micpath.2026.108318_bib43","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1128\/AAC.37.11.2459","article-title":"Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy","volume":"37","author":"Kar","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021635","article-title":"Miltefosine and nifuratel combination: a promising therapy for the treatment of Leishmania donovani visceral leishmaniasis","volume":"24","author":"Melcon-Fernandez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2026.108318_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2021.106260","article-title":"Anti-Leishmania activity of artesunate and combination effects with amphotericin B against leishmania (Mundinia) martiniquensis in vitro","volume":"226","author":"Intakhan","year":"2022","journal-title":"Acta Trop."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib39","article-title":"Post-Artesunate delayed hemolysis: a review of Current evidence","volume":"8","author":"Jaita","year":"2023","journal-title":"Trop. Med. Infect. Dis."},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib50","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s11686-022-00630-5","article-title":"The effect of BTK inhibitor ibrutinib on Leishmania infantum infection in vitro","volume":"67","author":"Mert","year":"2022","journal-title":"Acta Parasitol."},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/jiy552","article-title":"The potent ITK\/BTK inhibitor ibrutinib is effective for the treatment of experimental visceral leishmaniasis caused by Leishmania donovani","volume":"219","author":"Varikuti","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13030213","article-title":"Identification of novel flavonoids and Ansa-Macrolides with activities against Leishmania donovani through natural product Library screening","volume":"13","author":"Phan","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.micpath.2026.108318_bib52","article-title":"Febrifugine dihydrochloride as a new oral chemotherapeutic agent against visceral leishmaniasis infection","volume":"236\u2013237","author":"Pandey","year":"2022","journal-title":"Exp. Parasitol."},{"issue":"8","key":"10.1016\/j.micpath.2026.108318_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008575","article-title":"In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis","volume":"14","author":"Khanra","year":"2020","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"8","key":"10.1016\/j.micpath.2026.108318_bib105","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acsinfecdis.1c00139","article-title":"Ex vivo phenotypic screening of two small repurposing drug collections identifies Nifuratel as a potential new treatment against visceral and cutaneous leishmaniasis","volume":"7","author":"Dominguez-Asenjo","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"8","key":"10.1016\/j.micpath.2026.108318_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081980","article-title":"In vitro and in vivo activity of mTOR kinase and PI3K inhibitors against Leishmania donovani and Trypanosoma brucei","volume":"25","author":"Phan","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.micpath.2026.108318_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1066407","article-title":"Apigenin is a promising molecule for treatment of visceral leishmaniasis","volume":"13","author":"Emiliano","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.micpath.2026.108318_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156757","article-title":"Lupeol stimulates iNOS, TNF-alpha, and IL-10 expression in the U937 cell line infected with old-world Leishmania donovani","volume":"183","author":"Abbas","year":"2024","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.micpath.2026.108318_bib55","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/cbdd.14029","article-title":"Exploration of potential inhibitors for autophagy-related protein 8 as antileishmanial agents","volume":"99","author":"Rahman","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"11","key":"10.1016\/j.micpath.2026.108318_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24112072","article-title":"In vitro and in vivo effectiveness of carvacrol, thymol and linalool against Leishmania infantum","volume":"24","author":"Youssefi","year":"2019","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.micpath.2026.108318_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12784","article-title":"Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis","volume":"42","author":"Pereira","year":"2020","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.micpath.2026.108318_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111120","article-title":"Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis","volume":"134","author":"Ramos","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.micpath.2026.108318_bib109","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"eLife"},{"issue":"10\u201311","key":"10.1016\/j.micpath.2026.108318_bib61","article-title":"Antileishmanial potential of immunomodulator gallic acid against experimental murine visceral leishmaniasis","volume":"43","author":"Keshav","year":"2021","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.micpath.2026.108318_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2023.108555","article-title":"In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis","volume":"251","author":"Freitas","year":"2023","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.micpath.2026.108318_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114996","article-title":"Design and synthesis of novel halogen rich salicylanilides as potential antileishmanial agents","volume":"246","author":"Lal","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108318_bib111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpddr.2022.11.004","article-title":"Thiophene derivatives activity against the protozoan parasite Leishmania infantum","volume":"21","author":"Bigot","year":"2023","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"24","key":"10.1016\/j.micpath.2026.108318_bib112","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108318_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105414","article-title":"Novel phenanthridine amide analogs as potential anti-leishmanial agents: in vitro and in silico insights","volume":"117","author":"Nandikolla","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.micpath.2026.108318_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114577","article-title":"Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani","volume":"240","author":"McNamara","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/acsinfecdis.0c00546","article-title":"Antileishmanial chemotherapy through clemastine fumarate mediated inhibition of the Leishmania Inositol Phosphorylceramide synthase","volume":"7","author":"Mina","year":"2021","journal-title":"ACS Infect. Dis."},{"issue":"21","key":"10.1016\/j.micpath.2026.108318_bib72","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007235","article-title":"Oral activity of the antimalarial endoperoxide 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against Leishmania donovani complex","volume":"13","author":"Kwofie","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"35","key":"10.1016\/j.micpath.2026.108318_bib62","doi-asserted-by":"crossref","first-page":"37170","DOI":"10.1021\/acsomega.4c04517","article-title":"Novel diacyl-hydrazide compounds as potential therapeutics for visceral leishmaniasis","volume":"9","author":"Jandl","year":"2024","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.micpath.2026.108318_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02361-21","article-title":"Leishmania donovani dipeptidylcarboxypeptidase inhibitor as a potential oral treatment for visceral leishmaniasis","volume":"66","author":"Ramalingam","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpddr.2018.01.006","article-title":"In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series","volume":"8","author":"Van den Kerkhof","year":"2018","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.micpath.2026.108318_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115211","article-title":"Bestatin analogs-4-quinolinone hybrids as antileishmanial hits: design, repurposing rational, synthesis, in vitro and in silico studies","volume":"250","author":"Hassan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.micpath.2026.108318_bib65","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1021\/acs.jmedchem.2c01932","article-title":"Novel Pyrido[2',1':2,3]imidazo[4,5-c]quinoline derivative selectively poisons Leishmania donovani bisubunit topoisomerase 1 to inhibit the antimony-resistant leishmania infection in vivo","volume":"66","author":"Chowdhuri","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108318_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115049","article-title":"Design, synthesis, in vitro - in vivo biological evaluation of novel thiazolopyrimidine compounds as antileishmanial agent with PTR1 inhibition","volume":"247","author":"Istanbullu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"31","key":"10.1016\/j.micpath.2026.108318_bib68","doi-asserted-by":"crossref","first-page":"22587","DOI":"10.1039\/D4RA01904K","article-title":"Robust leishmanicidal upshot of some new diphenyl triazine-based molecules","volume":"14","author":"Singh","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.micpath.2026.108318_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115524","article-title":"Discovery, SAR and mechanistic studies of quinazolinone-based acetamide derivatives in experimental visceral leishmaniasis","volume":"257","author":"Ansari","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108318_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111632","article-title":"beta-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: a promising chemotype targeting visceral leishmaniasis","volume":"182","author":"Chandrakar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.micpath.2026.108318_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156373","article-title":"SHIP1 inhibition via 3-alpha-amino-cholestane enhances protection against Leishmania infection","volume":"171","author":"Chowdhury","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.micpath.2026.108318_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108952","article-title":"Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential","volume":"110","author":"Ribeiro","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"17","key":"10.1016\/j.micpath.2026.108318_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29174041","article-title":"Free radical production induced by Nitroimidazole compounds lead to cell death in Leishmania infantum amastigotes","volume":"29","author":"Andres-Rodriguez","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib75","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1873-3468.15016","article-title":"Identification of novel anti-leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach","volume":"599","author":"Sarma","year":"2025","journal-title":"FEBS Lett."},{"key":"10.1016\/j.micpath.2026.108318_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106009","article-title":"Energy metabolism as a target for cyclobenzaprine: a drug candidate against Visceral Leishmaniasis","volume":"127","author":"Lima","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"7619","key":"10.1016\/j.micpath.2026.108318_bib77","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"issue":"7717","key":"10.1016\/j.micpath.2026.108318_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.micpath.2026.108318_bib79","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.micpath.2026.108318_bib80","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.micpath.2026.108318_bib81","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.micpath.2026.108318_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of Bicyclic Nitro-drugs by a novel nitroreductase (NTR2) in leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"issue":"726","key":"10.1016\/j.micpath.2026.108318_bib84","doi-asserted-by":"crossref","first-page":"eadh9902","DOI":"10.1126\/scitranslmed.adh9902","article-title":"DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc(1)","volume":"15","author":"Braillard","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.micpath.2026.108318_bib82","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): a new lead for visceral leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.micpath.2026.108318_bib115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"2\u20133","key":"10.1016\/j.micpath.2026.108318_bib86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00430-021-00707-4","article-title":"Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis","volume":"210","author":"Costa","year":"2021","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.micpath.2026.108318_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.803048","article-title":"Metalloprotease Gp63-Targeting novel glycoside exhibits potential antileishmanial activity","volume":"12","author":"Chakrabarti","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5","key":"10.1016\/j.micpath.2026.108318_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000280","article-title":"Synthesis and in vitro antileishmanial efficacy of novel benzothiadiazine-1,1-dioxide derivatives","volume":"354","author":"Mangwegape","year":"2021","journal-title":"Arch. Pharm."},{"issue":"9","key":"10.1016\/j.micpath.2026.108318_bib87","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1039\/D3OB02091F","article-title":"Clemastine\/tamoxifen hybrids as easily accessible antileishmanial drug leads","volume":"22","author":"Agostino","year":"2024","journal-title":"Org. Biomol. Chem."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib88","first-page":"160","article-title":"Experimental chemotherapy with Allium sativum (Liliaceae) methanolic extract in rodents infected with Leishmania major and Leishmania donovani","volume":"47","author":"Wabwoba","year":"2010","journal-title":"J. Vector Borne Dis."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib89","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12639-021-01441-7","article-title":"Screening of medicinal plants unraveled the leishmanicidal credibility of Garcinia cowa; highlighting Norcowanin, a novel anti-leishmanial phytochemical through in-silico study","volume":"46","author":"Pyne","year":"2022","journal-title":"J. Parasit. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2026.108318_bib90","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s11686-020-00326-8","article-title":"Evaluation of in vitro and in vivo Protective Efficacy of Bauhinia variegata against Leishmania donovani in Murine Model","volume":"66","author":"Kaur","year":"2021","journal-title":"Acta Parasitol."},{"key":"10.1016\/j.micpath.2026.108318_bib91","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biopha.2018.12.053","article-title":"Serine protease inhibitors rich Coccinia grandis (L.) Voigt leaf extract induces protective immune responses in murine visceral leishmaniasis","volume":"111","author":"Pramanik","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77066-2","article-title":"Bioassay-based Corchorus capsularis L. leaf-derived beta-sitosterol exerts antileishmanial effects against Leishmania donovani by targeting trypanothione reductase","volume":"10","author":"Pramanik","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2026.108318_bib93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.exppara.2015.01.012","article-title":"Protective effect of Croton caudatus Geisel leaf extract against experimental visceral leishmaniasis induces proinflammatory cytokines in vitro and in vivo","volume":"151\u2013152","author":"Dey","year":"2015","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.micpath.2026.108318_bib94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1051\/parasite\/2021036","article-title":"In vitro and in vivo antileishmanial activity of beta-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis","volume":"28","author":"Freitas","year":"2021","journal-title":"Parasite"},{"key":"10.1016\/j.micpath.2026.108318_bib95","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2147\/IDR.S211721","article-title":"Intracellular anti-leishmanial effect of Spergulin-A, a triterpenoid saponin of Glinus oppositifolius","volume":"12","author":"Banerjee","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.micpath.2026.108318_bib96","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exppara.2019.02.013","article-title":"Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis","volume":"199","author":"Araujo","year":"2019","journal-title":"Exp. Parasitol."},{"issue":"1","key":"10.1016\/j.micpath.2026.108318_bib97","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1021\/acsinfecdis.2c00562","article-title":"Holanamine, a steroidal alkaloid from the bark of Holarrhena pubescens Wall. ex G. Don inhibits the growth of Leishmania donovani by targeting DNA topoisomerase 1B","volume":"9","author":"Goel","year":"2023","journal-title":"ACS Infect. Dis."},{"issue":"4","key":"10.1016\/j.micpath.2026.108318_bib102","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s11686-021-00416-1","article-title":"Potential anti-leishmanial activity of a semi-purified fraction isolated from the leaves of Parthenium hysterophorus","volume":"66","author":"Ghosh","year":"2021","journal-title":"Acta Parasitol."},{"issue":"10","key":"10.1016\/j.micpath.2026.108318_bib98","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/acsinfecdis.5b00081","article-title":"A novel sterol isolated from a plant used by Mayan traditional healers is effective in treatment of visceral leishmaniasis caused by Leishmania donovani","volume":"1","author":"Gupta","year":"2015","journal-title":"ACS Infect. Dis."},{"issue":"1\u20132","key":"10.1016\/j.micpath.2026.108318_bib99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jep.2004.12.032","article-title":"Efficacy of Desmodium gangeticum extract and its fractions against experimental visceral leishmaniasis","volume":"98","author":"Singh","year":"2005","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.micpath.2026.108318_bib100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jtcme.2023.06.003","article-title":"Prosopis juliflora (Sw.) DC.induces apoptotic-like programmed cell death in Leishmania donovani via over production of oxidative stress, mitochondrial dysfunction and ATP depletion","volume":"13","author":"Utage","year":"2023","journal-title":"J. Tradit. Complement. Med."},{"key":"10.1016\/j.micpath.2026.108318_bib101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcp.2017.05.002","article-title":"Voacamine alters Leishmania ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB","volume":"138","author":"Chowdhury","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.micpath.2026.108318_bib103","series-title":"WHO Guideline for the Treatment of Visceral Leishmaniasis in HIV co-infected Patients in East Africa and South-East Asia","article-title":"WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia","author":"Organization","year":"2022"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:55:39Z","timestamp":1777575339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401026000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":116,"alternative-id":["S0882401026000446"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108318","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging pharmacological treatments for visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108318"}}